Related references
Note: Only part of the references are listed.Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets A MAGNIFY-MS Substudy
Heinz Wiendl et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)
Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers
Mario Habek et al.
NEUROLOGY AND THERAPY (2023)
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
Sven G. Meuth et al.
EXPERT OPINION ON PHARMACOTHERAPY (2022)
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis MAGNIFY-MS
Nicola de Stefano et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
Peter Rieckmann et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2022)
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
Jose Fernandez-Velasco et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Highly effective disease-modifying treatment as initial MS therapy
Klaus Schmierer et al.
CURRENT OPINION IN NEUROLOGY (2021)
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
Leoni Rolfes et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis Data From 2 Different National Strategies
Tim Spelman et al.
JAMA NEUROLOGY (2021)
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Peter Rieckmann et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
Kimberley Allen-Philbey et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Health-care disparities for people with multiple sclerosis
Joanna Laurson-Doube et al.
LANCET NEUROLOGY (2020)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He et al.
LANCET NEUROLOGY (2020)
Severe skin reactions associated with cladribine in people with multiple sclerosis
M. Mateo-Casas et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Can We Improve the Monitoring of People With Multiple Sclerosis Using Simple Tools, Data Sharing, and Patient Engagement?
Kimberley Allen-Philbey et al.
FRONTIERS IN NEUROLOGY (2020)
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS
Tobias Moser et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
CSF neurofilament light chain testing as an aid to determine treatment strategies in MS
Saul Reyes et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
T. Leist et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Potential mechanisms of action related to the efficacy and safety of cladribine
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis
Daniel M. Hartung et al.
JAMA NEUROLOGY (2019)
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies
Zhifeng Mao et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
Dayo Afolabi et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis
Dayo Afolabi et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Bryan Ceronie et al.
JOURNAL OF NEUROLOGY (2018)
Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine
O. Yildiz et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
David Baker et al.
JAMA NEUROLOGY (2017)
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Cesar Alvarez-Gonzalez et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
David Baker et al.
EBIOMEDICINE (2017)
Both cladribine and alemtuzumab may effect MS via B-cell depletion
David Baker et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
Erin E. Longbrake et al.
JAMA NEUROLOGY (2016)
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
Julia Pakpoor et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
Arumugam Palanichamy et al.
JOURNAL OF IMMUNOLOGY (2014)
Neurofilament ELISA validation
Axel Petzold et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)